Enveric Biosciences (ENVB) Net Income towards Common Stockholders (2010 - 2026)
Enveric Biosciences (ENVB) posted Net Income towards Common Stockholders of -$1.6 million for Q1 2026, up 59.57% sequentially from -$4.0 million in Q4 2025, and up 25.24% YoY from -$1.3 million in Q1 2025.
Enveric Biosciences (ENVB) Net Income towards Common Stockholders (2010 - 2026) Analysis & Trends
Enveric Biosciences has reported Net Income towards Common Stockholders for 17 years, with the latest figure at -$1.6 million in Q1 2026.
- Quarterly Net Income towards Common Stockholders rose 25.24% year-over-year to -$1.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$11.6 million (down 24.48% YoY) and the FY2025 annual result came in at -$12.1 million, down 26.7% from the prior year.
- Net Income towards Common Stockholders improved to -$1.6 million in Q1 2026 per ENVB's latest filing, from -$4.0 million in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at -$1.6 million in Q1 2026 and troughed at -$8.8 million in Q4 2022.
- A 5-year average of -$3.5 million and a median of -$2.9 million in 2022 frame the typical range for Net Income towards Common Stockholders.
- The widest YoY moves for Net Income towards Common Stockholders: up 79.1% in 2022, down 216.23% in 2022.
- Over 5 years, Net Income towards Common Stockholders stood at -$8.8 million in 2022, then jumped by 60.96% to -$3.4 million in 2023, then climbed by 8.19% to -$3.2 million in 2024, then declined by 28.07% to -$4.0 million in 2025, then jumped by 59.57% to -$1.6 million in 2026.
- According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$1.6 million, -$4.0 million, and -$3.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Enveric Biosciences | 5.66 Mn | -2.64 Mn | - | -3.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.63 Mn |
| Dec 31, 2025 | -4.04 Mn |
| Sep 30, 2025 | -3.39 Mn |
| Jun 30, 2025 | -2.52 Mn |
| Mar 31, 2025 | -2.18 Mn |
| Dec 31, 2024 | -3.15 Mn |
| Sep 30, 2024 | -2.08 Mn |
| Jun 30, 2024 | -1.88 Mn |
| Mar 31, 2024 | -2.46 Mn |
| Dec 31, 2023 | -3.44 Mn |
| Sep 30, 2023 | -2.82 Mn |
| Jun 30, 2023 | -6.40 Mn |
| Mar 31, 2023 | -4.80 Mn |
| Dec 31, 2022 | -8.80 Mn |
| Sep 30, 2022 | -2.60 Mn |
| Jun 30, 2022 | -2.87 Mn |
| Mar 31, 2022 | -4.52 Mn |
| Dec 31, 2021 | -42.11 Mn |
| Sep 30, 2021 | -2.71 Mn |
| Jun 30, 2021 | -908,289.00 |